{"ticker": {"uuid": "e9e1c105-77e0-49ee-9fa9-42436ea996bf", "symbol": "GMAB", "name": "Genmab AS", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Genmab (GMAB)", "summary": "Healthcare sector analysts have issued bullish sentiments on several companies, including Chemomab Therapeutics (CMMB) and Genmab (GMAB). Maxim Group maintained a Buy rating on Chemomab with a $5.00 price target, while William Blair reiterated a Buy rating on Genmab, which has a ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BIIB-Q/pressreleases/3300623/analysts-are-bullish-on-top-healthcare-stocks-chemomab-therapeutics-cmmb-genmab-gmab/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T16:42:59", "published_display": "15 Jul 2026 16:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab's Darzalex Generates $4.21 Billion in Q2 Net Trade Sales", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/genmab-apos-darzalex-generates-4-112044382.html", "source_name": "MT Newswires", "published_at": "2026-07-15T11:20:44+00:00", "published_display": "15 Jul 2026 11:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (Nasdaq: GMAB) reports USD 4,207 million Q2 DARZALEX sales", "summary": "Genmab A/S reported worldwide net trade sales of its drug DARZALEX (daratumumab), including DARZALEX FASPRO, reached USD 4,207 million in the second quarter of 2026. This total includes USD 2,435 million from U.S. sales and USD 1,772 million from the rest of the world. Genmab rec", "url": "https://www.stocktitan.net/sec-filings/GMAB/6-k-genmab-a-s-current-report-foreign-issuer-7bac9c6caaf9.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:40:39", "published_display": "15 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Announces Net Sales of DARZALEX\u00ae (daratumumab) for Second Quarter of 2026", "summary": "Genmab announced that worldwide net trade sales of DARZALEX (daratumumab) for the second quarter of 2026 totaled USD 4,207 million. This figure includes sales of both intravenous and subcutaneous products, as reported by Johnson & Johnson. Genmab receives royalties on these globa", "url": "https://www.manilatimes.net/2026/07/15/tmt-newswire/globenewswire/genmab-announces-net-sales-of-darzalex-daratumumab-for-second-quarter-of-2026/2384865", "source_name": "The Manila Times", "published_at": "2026-07-15T10:40:39", "published_display": "15 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "William Blair Maintains Genmab(GMAB.US) With Buy Rating", "summary": "William Blair has reiterated its Buy rating for Genmab (GMAB.US). This indicates a continued positive outlook on the company's stock from the investment firm.", "url": "https://www.moomoo.com/news/post/72951177/william-blair-maintains-genmab-gmabus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-07-15T06:12:27", "published_display": "15 Jul 2026 06:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab stock reflects biotech growth focus for long-term investors", "summary": "Genmab stock offers investors a pure-play opportunity in antibody-based cancer and immune therapies, leveraging a royalty-driven revenue model. The Danish biotech's dual Nasdaq listings provide US investors access to its expanding pipeline of differentiated antibody formats and a", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/genmab-stock-reflects-biotech-growth-focus-for-long-term-investors/69764046", "source_name": "Ad Hoc News", "published_at": "2026-07-14T05:13:16", "published_display": "14 Jul 2026 05:13", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Genmab A/S (GMAB) Stock Analysis: Unlocking A 26.68% Upside With Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNT3JiNVJ4X3lyYnlIVXNFWUZ5MVBQb0g5cGtKbGZzWjN4NlBkN3VRa0hnb1B3UVdTV2NHSGZKcVJaaVBRM2NFRFpXdXU4QzdZeGZMQ3dsRzUyalBNTjFTRUxBa3ZGVFl4VzRtNUs3UUVESzdMOTZTNzBQaDc5VlhnVDRkRHhjazFTR2xfX1F6eEdDcld3ZUJHaE5rQXZ1RWk2TnJCeXpmc3Z5V3VTY0MxZmY3SlpiRnc1OU1ZRjFTa2R3c09MdjZBNQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:19:12+00:00", "published_display": "13 Jul 2026 09:19", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New data on Novo's hemophilia treatment show few and mild side effects", "summary": "New long-term data for Novo Nordisk's antihemorrhagic drug mim8, developed in collaboration with Genmab, indicate a reduction in bleeding episodes. The treatment also shows a favorable safety profile with few and mild side effects across all age groups. However, the full article ", "url": "https://medwatch.com/News/Pharma___Biotech/article19471906.ece", "source_name": "MedWatch", "published_at": "2026-07-13T08:11:26", "published_display": "13 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?", "summary": "H.C. Wainwright analyst Raghuram Selvaraju increased the price target for Genmab A/S (GMAB) to $40 from $38, reaffirming a Buy rating following positive Epkinly DLBCL-4 trial results and increased regulatory approval likelihood. Additionally, the European Commission approved mark", "url": "https://finance.yahoo.com/healthcare/articles/genmab-gmab-stock-undervalued-positive-150448785.html", "source_name": "Market source", "published_at": "2026-07-08T15:10:05", "published_display": "08 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Announces TEPKINLY\u00ae (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma", "summary": "Genmab announced that the European Commission has approved TEPKINLY\u00ae (epcoritamab) in combination with lenalidomide and rituximab (R2) for treating adult patients with relapsed or refractory follicular lymphoma (FL). This approval, based on the Phase 3 EPCORE\u00ae FL-1 trial, establi", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322680/0/en/genmab-announces-tepkinly-epcoritamab-in-combination-with-lenalidomide-and-rituximab-is-approved-by-the-european-commission-for-the-treatment-of-relapsed-or-refractory-follicular-l.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T17:11:26", "published_display": "07 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Stock Recovery Not To Be Mistaken For New Uptrend", "summary": "Genmab, a biotech company, has seen its stock recover over the past two months due to optimism surrounding its blood-cancer drug Epkinly, despite being down 43.5% from its late-2022 high. However, an Elliott Wave analysis suggests this recovery is not a new uptrend but rather a w", "url": "https://ewminteractive.com/genmab-stock-recovery-mistaken-new-uptrend", "source_name": "EWM Interactive", "published_at": "2026-07-07T14:40:09", "published_display": "07 Jul 2026 14:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Secures EU Approval for Drug Combination Intended for Relapsed or Refractory Follicular Lymphoma", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/genmab-secures-eu-approval-drug-085421979.html", "source_name": "MT Newswires", "published_at": "2026-07-07T08:54:21+00:00", "published_display": "07 Jul 2026 08:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Announces TEPKINLY\u00ae (epcoritamab) in Combination", "summary": "Genmab announced that the European Commission has approved TEPKINLY\u00ae (epcoritamab) in combination with lenalidomide and rituximab (R2) for treating adult patients with relapsed or refractory follicular lymphoma. This marks the first and only bispecific-based therapy approved in E", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322680/0/en/Genmab-Announces-TEPKINLY-epcoritamab-in-Combination-with-Lenalidomide-and-Rituximab-is-Approved-by-the-European-Commission-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-L.ht", "source_name": "GlobeNewswire", "published_at": "2026-07-07T03:40:09", "published_display": "07 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Announces Tepkinly\u00ae In Combination With Lenalidomide And Rituximab Is Approved By The European Commission", "summary": "Genmab announced that the European Commission has approved Tepkinly\u00ae in combination with lenalidomide and rituximab. This approval is a significant regulatory milestone for the company and its oncology treatment. The drug regimen is now cleared for use within the European Union.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA1PNPGB:0-genmab-announces-tepkinly-in-combination-with-lenalidomide-and-rituximab-is-approved-by-the-european-commission/", "source_name": "TradingView", "published_at": "2026-07-06T18:10:33", "published_display": "06 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 85, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S", "summary": "Genmab A/S announced that the European Commission has granted marketing authorization for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for the treatment of relapsed or refractory follicular lymphoma (FL). This approval is based on the Phase 3 EPCORE FL-1 ", "url": "https://via.ritzau.dk/pressemeddelelse/15036655/genmab-as?publisherId=90446&lang=en", "source_name": "Via Ritzau", "published_at": "2026-07-06T18:10:33", "published_display": "06 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BNP Paribas raises the target price for Genmab to 2,500 Danish kroner (2,400), reiterates outperform - BN", "summary": "BNP Paribas has increased its target price for Genmab to 2,500 Danish kroner, up from 2,400, while maintaining an \"outperform\" rating. This adjustment reflects a positive outlook on the biotechnology company's future performance. The article also provides recent news on Genmab's ", "url": "https://www.marketscreener.com/news/bnp-paribas-raises-the-target-price-for-genmab-to-2-500-danish-kroner-2-400-reiterates-outperform-ce7f5edbd888f421", "source_name": "www.marketscreener.com", "published_at": "2026-07-06T13:10:47", "published_display": "06 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Europe approves Genmab's TEPKINLY combo for relapsed follicular lymphoma", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNQnU3NnNXVm9lM3FhOFF2MUNidnZKaEZQeFBLWUZIQXRvWFp2YnJUNDNMaDgzSDJPb1ljWWw3UDd1a0xjQko4TnRITkNfZTI3dHZ6N2gybGs2SUJIdzFZZ1N4UkN1SlI2Z2JVQVBmd3N4dklJcFdoVEdxWVd6Tms0LUtlRURFY0ZyVTJnM2JuNTRqYklOQS1mYURLUnViV042S202SlBHQkZJRzJnWTd0TEpn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GMAB - Genmab ADR Earnings", "summary": "This Finviz article provides a detailed financial overview of Genmab ADR (GMAB), including its last closing price, key financial metrics like market cap, income, sales, P/E ratio, and EPS. It also lists performance indicators, insider ownership, institutional ownership, and analy", "url": "https://finviz.com/stock?t=GMAB&p=d&b=2&r=m3&ty=ea", "source_name": "Finviz", "published_at": "2026-07-04T10:39:10", "published_display": "04 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Genmab stock price target on trial success", "summary": "H.C. Wainwright has increased its price target for Genmab A/S shares to $40 from $38, maintaining a Buy rating, following successful trial results for the drug EPKINLY. The trial demonstrated a statistically significant improvement in progression-free survival for diffuse large B", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-genmab-stock-price-target-on-trial-success-93CH-4772913", "source_name": "Investing.com", "published_at": "2026-07-02T14:10:24", "published_display": "02 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab shares rise following positive epcoritamab phase 3 data", "summary": "Genmab shares rose after the company and AbbVie announced positive phase 3 results for their drug epcoritamab. The drug, in combination with lenalidomide, significantly improved progression-free survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL", "url": "https://european-biotechnology.com/latest-news/genmab-positive-phase-3-data-epcoritamab-combination/", "source_name": "European Biotechnology Magazine", "published_at": "2026-07-01T06:41:12", "published_display": "01 Jul 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab and AbbVie\u2019s Epkinly combo improves PFS in second-line DLBCL trial", "summary": "Genmab and AbbVie have announced positive topline results from their Phase III EPCORE DLBCL-4 trial, showing that Epkinly in combination with Revlimid significantly improved progression-free survival in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Thi", "url": "https://www.clinicaltrialsarena.com/news/dlbcl-epkinly-second-line-data/", "source_name": "Clinical Trials Arena", "published_at": "2026-07-01T01:40:18", "published_display": "01 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie, Genmab Blood-Cancer Drug Has Competitive Profile -- Market Talk", "summary": "AbbVie and Genmab's investigational blood cancer drug, epcoritamab, has shown a competitive profile in a Phase 1/2 study, according to analysts at Jefferies. The drug, a bispecific antibody, demonstrated a 60% complete response rate in patients with large B-cell lymphoma, reinfor", "url": "https://www.moomoo.com/news/post/72269984/abbvie-genmab-blood-cancer-drug-has-competitive-profile-market-talk", "source_name": "Moomoo", "published_at": "2026-07-01T01:09:27", "published_display": "01 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After monotherapy failure, AbbVie and Genmab tout Epkinly combo win in DLBCL", "summary": "AbbVie and Genmab's Epkinly, despite a recent monotherapy failure, showed a significant win in a Phase 3 combination trial for diffuse large B-cell lymphoma (DLBCL). The drug, combined with lenalidomide, reduced the risk of progression or death by 60% compared to the R-GemOx regi", "url": "https://www.fiercepharma.com/pharma/after-monotherapy-failure-abbvie-and-genmab-tout-epkinly-combo-win-dlbcl", "source_name": "Fierce Pharma", "published_at": "2026-06-30T13:39:58", "published_display": "30 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival", "summary": "Genmab announced positive topline results from its Phase 3 EPCORE DLBCL-4 trial, showing that epcoritamab combined with lenalidomide significantly improved progression-free survival in patients with relapsed/refractory diffuse large B-cell lymphoma. The combination reduced the ri", "url": "https://www.businesswire.com/news/home/20260629433290/en/Genmab-Announces-Positive-Phase-3-Results-for-Epcoritamab-Plus-Lenalidomide-in-Patients-with-RelapsedRefractory-Diffuse-Large-B-Cell-Lymphoma-Demonstrating-Statistically-Significant-Improvement-in-Progression-Free-Survival", "source_name": "Business Wire", "published_at": "2026-06-30T12:41:12", "published_display": "30 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial", "summary": "Genmab's shares increased in European morning trading after its drug combination with partner AbbVie met the primary goal in a late-stage clinical trial for lymphoma. The stock rose 6%, recovering some year-to-date losses, though it remains down 10% since the start of 2026. AbbVi", "url": "https://www.wsj.com/health/pharma/genmab-shares-climb-after-lymphoma-therapy-hits-goal-in-trial-64ebf887", "source_name": "WSJ", "published_at": "2026-06-30T09:39:31", "published_display": "30 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab stock rallies after Epkinly shows strong results in 2L lymphoma trial", "summary": "Genmab shares surged after its drug Epkinly, combined with lenalidomide, delivered strong interim data in a late-stage trial for second-line diffuse large B-cell lymphoma. The results showed a progression-free survival hazard ratio of 0.40, easing previous investor concerns after", "url": "https://www.investing.com/news/stock-market-news/genmab-stock-rallies-after-epkinly-shows-strong-results-in-2l-lymphoma-trial-4767021", "source_name": "Investing.com", "published_at": "2026-06-30T08:39:32", "published_display": "30 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab\u2019s Epcoritamab Plus Lenalidomide Meets Phase 3 Goal in Relapsed DLBCL", "summary": "Genmab's Phase 3 EPCORE DLBCL-4 trial for epcoritamab plus lenalidomide in relapsed or refractory DLBCL patients met its primary endpoint, showing a 60% reduction in disease progression or death risk compared to R-GemOx. This significant result, with a hazard ratio of 0.40 (U.S.)", "url": "https://www.clinicaltrialvanguard.com/news/genmabs-epcoritamab-plus-lenalidomide-meets-phase-3-goal-in-relapsed-dlbcl/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-06-30T06:39:32", "published_display": "30 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab reports positive phase 3 trial results for lymphoma drug", "summary": "Genmab A/S announced positive Phase 3 trial results for its lymphoma drug epcoritamab, showing statistically significant improvement in progression-free survival for patients with relapsed or refractory diffuse large B-cell lymphoma. The company reported strong financial momentum", "url": "https://www.investing.com/news/company-news/genmab-reports-positive-phase-3-trial-results-for-lymphoma-drug-93CH-4766234", "source_name": "Investing.com", "published_at": "2026-06-30T00:12:41", "published_display": "30 Jun 2026 00:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab lymphoma trial cuts progression risk 60% in phase 3 study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNckZUcExPdF92eDZNTC1FamFmaUhwUUFiYTE0OGVxN1FoVFFUMHo4ZEJGS05ZNzFDaTB5RkxnT05lZVplV3BjVWtKVDdHZ3kyMEVNdjJVWWVSSVFhellVR19xRy1TZkd4Q0Q2aktLMThLRGpEYUtjdjdkYkhhUTR4WTRqSTBSempudWxiaWVpbGgzY3BUb3hCYXJ3VE92Ym9ZcDRqWmdQZll1SUhralprczkzeGwwVi1w?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (NASDAQ: GMAB) issues 185 new shares from employee warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQcFd2MVlaM2k1S0NWcFhRSTBLb2ZLZTdZSVB4bjRIUjVvT3VJUUc0MHpyZGZfRGgyYzRjZmFQMEl4ZTlET3pYM3ZBcXRHT0R1cTJYeDBWX3VkTUZ4Y21IblBFZE5kMlc4NWxsOFRrQ25DVXQ4U282TmF4YldiLUVUVzRQTWRnN3pORldpeXhCTFZ0VXBlWXJnWG1PRFcwOTY1YTNXTEh6SVRiQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab\u2019s epcoritamab phase 3 lymphoma results set for ASCO and EHA 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSEdhWGhwYXZIaDRubmctcF9WdTNQX3FfMjlULWJySy1ZLW9VWVNYX0JsWkRLdm5LUHlROGZ5U3llRktocVhPZ2tKbHpLal9rNFBaZFhHTEh2c29qVXNXX2RsaUIzNkw2R0pydkFGcWxZS1NMZndYOFVuQ2dNX085Y1VKbi1reG9ySEVISGJzMXo2TVVNQTZmMVh0UFZrcXVMQUdNNERVYnF1NE1uUUJCSHhCUUE3WVdBVUFGTw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNLWV6MExvM1NSUEJ5eE5CaU1tZERrby1IaFFnN2IxR2xpWFo0NjVZczY1VUkyT3g4NWI5TU8tMm5iaGVQdU90eEVmMXhoRzhzQnBBd3hSTUdHaTJRSFo3REJHLUpLWjRPSVRPYVNlOFl5SGc5d0VCM1Q2b3JmZ29DOGFla0RManlPdFR4bEVLRnAxbEljNThRdU90aDczdw?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Capital Increase in Genmab as a Result of Employee Warrant Exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPQlJRQzVVdU1IM1ZLT1ZYZXlMWkMzR2ZrUFREUU0zaDRINVVxc1g1RU1zUVQ2MzRmVlZzcTR4dzF1ZG5kVWFEXzhVWktCWHktUDRnbmZiSEl1UmVVbUMyTzZHZlFDd0F3T3J0REZtUEYyWHpPaXo5NTBROVVRNHlpcW9vcTJQcHNhX1NTTjh1OHVXWUcwWkljLXBUdkxNNDc2bENESFhfbw?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Genmab plunges after financial report: Analyst cites uncertainty surrounding clinical trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9lbXZVemZVQUV1VkdYb2pQWTBERzFHdHZzcHIxTVVyX0VwRFIyWWZOS2N0TVdkUVIwRmY1dHdRRzRPY2o5OGx5dDZiQjJPUGJaQmI0MUhrT1V5LWR3bjcwOEQ1TEM5ZGNhWW9lWVo2MA?oc=5", "source_name": "medwatch.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi\u2011Year Share Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOUjhiOXlYYkF3RHFBUXVPY2tTbzQ4VlJCandIeDhHMmJrZzl5YWIyVDA2UmRXTTFSLWFlMnNrRnFlcHROUVdZUnVsVHBaSTljOEphVFM2bkhtZWJTbk1fekc2OWVYZnRZLU9VZ3FFT1ZrOVhsNlZxdzFrei1HTWxtdk1lazVfN0xzY0x1Z2ZidWFaNkk4UUdUYUlhNA?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (GMAB) stock falls on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNaUh6a2RmMnNjNFB2VnI3MTNTTGlfWTl6WExfRFhzRHRJOHJhdzhYbkNld0NaLUFpekFfemdPbmdSM1pCaG5hcEZTaGQ2WEhZWGJqSXZReWh0djNMZDlrUjZQSWZVbHJaRERwQ0dpRkFBclBZZ29HT1Fvc2VueFFvMG8wR2hMUEZKeDIzZlVaWEhpQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Rated Outperform on Oncology Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZmpxd1NpbTVHX3pZc2VyVjVpWVliSUNWYmFLbmZObkk2ejdmc0k1ME9ZdEwwZjFhVkNIblYyMTJBdWF5NlZfeVVueldkbU9Ydi1EUERPYnVsVUp0cm0wRmZqcXdwOXpZV2tyVXFndWppZHg4a21GN0JQQW9RNzVlUnJpMndkZHJreXNOUEFxZ2VCaHE1ZkhMTDJFT083X1FDMjdneDVvRnBRZw?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Genmab\u2019s (CPSE:GMAB) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQOXhrV3ZBMURTTVVITTdQZ1Z3YzYxUE40alV4bEJ1VjN4N19rbTdmdkN1NWVWdThHeXFiOE5WNnotWEFVcE1GVTBIS1dOdzZPNVFWdUxmLUdqM3VCbHdWa09hWGJ5R0JUek9OQnRDZFBISnNfU3NrblpYTGtuTGZKcFFtcXpKaldOT1VMbE9aNHR0WnI3WmVxYjhWd1g?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab Readouts", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNQk9kRTlPdmQtaF9uUVhlTXhHSjIxd1JJZ2toUEJTUXQ0c3k4N3dqNlNva0VvREJYYWVwaHVNQTBHUm5zbVd6MGZ6OHQya1JPRk5QZ0JvUnhGU21OR1hZNmxQR0FOTDRPTElWUnZ3aThqYXhBdU1aa1ZodVgxWGhMTDRoemtoeFd6TFdnd2hLUi1nN2FFUlpBSkg1ZFVzNVJl?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Constitution of the Board of Directors in Genmab A/S and", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogJBVV95cUxQbUlOd0tVamZ5SkFqV2NYcWVlTU5CenRhVjNKYU50Y1pGZ1VKcnFMbkVaZW10VGZ1OW9Rb2NPc2YwSnJpRXYtNWFyNmdkTjB3OVdCUmw0ZDRSbF91OGxWRWVVaFBoSWU1cEVybl9DNVNFZEVZbXJRYWtSSlV0bkpMRThiYWE2SGNaS1U2YUJzZEJBaFExMFdLR0FPenNXakhWZ0Z6VkkzZG1GTm9CM0RoQ2szN3gyVkp3MkFYWUdSQmdIWTJjSDloUzFtZnVFWDlUS01yQmlIT3lpaDlqeW5KTnhWZmljNHk2R05TbGptRXg4c3BHNXFJdHZRNlRJdnRfaFZJU1I2ZDBvdGJPSmxLeHZBV1o1LVhUUXNkd1RUdW95Zw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNdnJwT19rRjVEN3JfUnBWTlJ1bUZZUG1tRWJBX21KYWtDcmJWWkw5MnVOaWgwR0JKeXQwUkU4cU9yOG54R0NiMnoxc1czbjV6eXZyOVV5eHMxb1dtbjExbmUtNXp1UHFocVUwZjFrRHhHYlVDb2xfd3ZNYnVIbGlVczM5aFh6bF82WmJ5eWlpVHdqWHJfa3Z1Vnp2ZDRmRHBaM2RQZ1NNOWRRUzE5QWh3SW8zcFExUDZvRkVKZVRSdVBsZw?oc=5", "source_name": "ChartMill", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Genmab (CPSE:GMAB) Narrative Is Shifting As 2026 Catalyst Risks Build", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNOTZnQTlGYnljWm1NT25BN2tRQVl4dzNqZWIyZU5mOG04MHE1WWJCZTVad2RIaFdXS3l6QUJuTTg0ZjBNWjh0SUNfeU1ZTUtubWtyYWZFZnozWWZjZWxDaWtmQXNYYXdoVWt3UjhIbURYM19CS21FUkZLUl95Tmt1TlljR0dpLW5S?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNcm5lb2IwQUhyVEFlYmFRaG40U0lzUzdOVU5HVzd3ZDFiQk96RHdLWUxVTXcwUGt0MUhCZkloUjQ4akwwUG5WMzZZSGN2N252ajZyMmgyTGp0OExvYlZJby1UQUtFSlhYRUVkQ210YmZkNE8yVXBnQ0RVYnRFMXhMT09R?oc=5", "source_name": "Market source", "published_at": "2026-02-20T08:00:00+00:00", "published_display": "20 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Where is Genmab A/S (GMAB) Headed According to Wall Street?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPOGV2M016ZC13NEpIa05vR1ZUNHpiR3Q0amVPajRJRHdqczBYWGhjYVdydFhmRWhYWlZnaGVSYUhnX2tKNVo5cDU5bEdfaDJYTWV0WFdJMWVmY21ZbUVRSjJ1cGRNMTJMV0tpUmFRNVU2SDNmX0hKZmJoR2JMMlZUQ1Z0dS1lbTA?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB)\u2019s Future Potential Underappreciated by Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOWWlrWWpHU1pOaVU2TlAzaUhtQ19uc3kzU0htYzJyYUJGeTJCRlI3RHRqT21VYzUzYVYxVGhvQVFaWDhtVmtzQktDVUNCS3pjUGxYeFBfbkU4eG1zRnd2X1RKRVhmbTREeFI5NTZ2azFvdW92LTE2dmt1WUpOV3NDRWlNc2M1bWhFYUpwcndmWVhGeWxWOFE?oc=5", "source_name": "Market source", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxOTmUtQjcyV1RXS0ZpVW9fN3BRcHpSd0NwQkxyN1ZLT2tpa2JGX1FSYWhmTm91OEtESktublRWdkFxRkhBYkxiT0NMOVY2UzVGcGlHazJQWC1Nd200a1VpMFBoeWlyaWdvMDUtbm5MRTRuczZBM0tmVk9pcklCcy1YTGNzSzNQT00yYmkzMWhudHd0LUFUSWgxMmJyT3VhTGZ1T05ObWxOZ2FWVXc5LWRZLTZyaTl6Y2NkLS15d2laZUI4V0N0ZUhkTlJMVVNtUmxUWGQ3dVFSUFNrS0VfVlllUHQyd0RNRGMtUWJIaWdRUDFkM1h1MzdLblEzWQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9nUGpGYzh6QmdvN1BZWHdXekdheFpxVkYyYlVPQnBVWmFTQVlMOHJNSGhPbFJsMnlLS2MwTkJtX29uLW5RdklPQUFiazBYQkFtM1Vr?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T22:48:32+00:00", "published_display": "24 Apr 2025 22:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Genmab (GMAB)", "summary": "Healthcare sector analysts have issued bullish sentiments on several companies, including Chemomab Therapeutics (CMMB) and Genmab (GMAB). Maxim Group maintained a Buy rating on Chemomab with a $5.00 price target, while William Blair reiterated a Buy rating on Genmab, which has a ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BIIB-Q/pressreleases/3300623/analysts-are-bullish-on-top-healthcare-stocks-chemomab-therapeutics-cmmb-genmab-gmab/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T16:42:59", "published_display": "15 Jul 2026 16:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab's Darzalex Generates $4.21 Billion in Q2 Net Trade Sales", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/genmab-apos-darzalex-generates-4-112044382.html", "source_name": "MT Newswires", "published_at": "2026-07-15T11:20:44+00:00", "published_display": "15 Jul 2026 11:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (Nasdaq: GMAB) reports USD 4,207 million Q2 DARZALEX sales", "summary": "Genmab A/S reported worldwide net trade sales of its drug DARZALEX (daratumumab), including DARZALEX FASPRO, reached USD 4,207 million in the second quarter of 2026. This total includes USD 2,435 million from U.S. sales and USD 1,772 million from the rest of the world. Genmab rec", "url": "https://www.stocktitan.net/sec-filings/GMAB/6-k-genmab-a-s-current-report-foreign-issuer-7bac9c6caaf9.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:40:39", "published_display": "15 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Announces Net Sales of DARZALEX\u00ae (daratumumab) for Second Quarter of 2026", "summary": "Genmab announced that worldwide net trade sales of DARZALEX (daratumumab) for the second quarter of 2026 totaled USD 4,207 million. This figure includes sales of both intravenous and subcutaneous products, as reported by Johnson & Johnson. Genmab receives royalties on these globa", "url": "https://www.manilatimes.net/2026/07/15/tmt-newswire/globenewswire/genmab-announces-net-sales-of-darzalex-daratumumab-for-second-quarter-of-2026/2384865", "source_name": "The Manila Times", "published_at": "2026-07-15T10:40:39", "published_display": "15 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "William Blair Maintains Genmab(GMAB.US) With Buy Rating", "summary": "William Blair has reiterated its Buy rating for Genmab (GMAB.US). This indicates a continued positive outlook on the company's stock from the investment firm.", "url": "https://www.moomoo.com/news/post/72951177/william-blair-maintains-genmab-gmabus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-07-15T06:12:27", "published_display": "15 Jul 2026 06:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab stock reflects biotech growth focus for long-term investors", "summary": "Genmab stock offers investors a pure-play opportunity in antibody-based cancer and immune therapies, leveraging a royalty-driven revenue model. The Danish biotech's dual Nasdaq listings provide US investors access to its expanding pipeline of differentiated antibody formats and a", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/genmab-stock-reflects-biotech-growth-focus-for-long-term-investors/69764046", "source_name": "Ad Hoc News", "published_at": "2026-07-14T05:13:16", "published_display": "14 Jul 2026 05:13", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (GMAB) Stock Analysis: Unlocking A 26.68% Upside With Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNT3JiNVJ4X3lyYnlIVXNFWUZ5MVBQb0g5cGtKbGZzWjN4NlBkN3VRa0hnb1B3UVdTV2NHSGZKcVJaaVBRM2NFRFpXdXU4QzdZeGZMQ3dsRzUyalBNTjFTRUxBa3ZGVFl4VzRtNUs3UUVESzdMOTZTNzBQaDc5VlhnVDRkRHhjazFTR2xfX1F6eEdDcld3ZUJHaE5rQXZ1RWk2TnJCeXpmc3Z5V3VTY0MxZmY3SlpiRnc1OU1ZRjFTa2R3c09MdjZBNQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:19:12+00:00", "published_display": "13 Jul 2026 09:19", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New data on Novo's hemophilia treatment show few and mild side effects", "summary": "New long-term data for Novo Nordisk's antihemorrhagic drug mim8, developed in collaboration with Genmab, indicate a reduction in bleeding episodes. The treatment also shows a favorable safety profile with few and mild side effects across all age groups. However, the full article ", "url": "https://medwatch.com/News/Pharma___Biotech/article19471906.ece", "source_name": "MedWatch", "published_at": "2026-07-13T08:11:26", "published_display": "13 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?", "summary": "H.C. Wainwright analyst Raghuram Selvaraju increased the price target for Genmab A/S (GMAB) to $40 from $38, reaffirming a Buy rating following positive Epkinly DLBCL-4 trial results and increased regulatory approval likelihood. Additionally, the European Commission approved mark", "url": "https://finance.yahoo.com/healthcare/articles/genmab-gmab-stock-undervalued-positive-150448785.html", "source_name": "Market source", "published_at": "2026-07-08T15:10:05", "published_display": "08 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Announces TEPKINLY\u00ae (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma", "summary": "Genmab announced that the European Commission has approved TEPKINLY\u00ae (epcoritamab) in combination with lenalidomide and rituximab (R2) for treating adult patients with relapsed or refractory follicular lymphoma (FL). This approval, based on the Phase 3 EPCORE\u00ae FL-1 trial, establi", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322680/0/en/genmab-announces-tepkinly-epcoritamab-in-combination-with-lenalidomide-and-rituximab-is-approved-by-the-european-commission-for-the-treatment-of-relapsed-or-refractory-follicular-l.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T17:11:26", "published_display": "07 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Stock Recovery Not To Be Mistaken For New Uptrend", "summary": "Genmab, a biotech company, has seen its stock recover over the past two months due to optimism surrounding its blood-cancer drug Epkinly, despite being down 43.5% from its late-2022 high. However, an Elliott Wave analysis suggests this recovery is not a new uptrend but rather a w", "url": "https://ewminteractive.com/genmab-stock-recovery-mistaken-new-uptrend", "source_name": "EWM Interactive", "published_at": "2026-07-07T14:40:09", "published_display": "07 Jul 2026 14:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Secures EU Approval for Drug Combination Intended for Relapsed or Refractory Follicular Lymphoma", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/genmab-secures-eu-approval-drug-085421979.html", "source_name": "MT Newswires", "published_at": "2026-07-07T08:54:21+00:00", "published_display": "07 Jul 2026 08:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Announces TEPKINLY\u00ae (epcoritamab) in Combination", "summary": "Genmab announced that the European Commission has approved TEPKINLY\u00ae (epcoritamab) in combination with lenalidomide and rituximab (R2) for treating adult patients with relapsed or refractory follicular lymphoma. This marks the first and only bispecific-based therapy approved in E", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322680/0/en/Genmab-Announces-TEPKINLY-epcoritamab-in-Combination-with-Lenalidomide-and-Rituximab-is-Approved-by-the-European-Commission-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-L.ht", "source_name": "GlobeNewswire", "published_at": "2026-07-07T03:40:09", "published_display": "07 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Announces Tepkinly\u00ae In Combination With Lenalidomide And Rituximab Is Approved By The European Commission", "summary": "Genmab announced that the European Commission has approved Tepkinly\u00ae in combination with lenalidomide and rituximab. This approval is a significant regulatory milestone for the company and its oncology treatment. The drug regimen is now cleared for use within the European Union.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA1PNPGB:0-genmab-announces-tepkinly-in-combination-with-lenalidomide-and-rituximab-is-approved-by-the-european-commission/", "source_name": "TradingView", "published_at": "2026-07-06T18:10:33", "published_display": "06 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 85, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S", "summary": "Genmab A/S announced that the European Commission has granted marketing authorization for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for the treatment of relapsed or refractory follicular lymphoma (FL). This approval is based on the Phase 3 EPCORE FL-1 ", "url": "https://via.ritzau.dk/pressemeddelelse/15036655/genmab-as?publisherId=90446&lang=en", "source_name": "Via Ritzau", "published_at": "2026-07-06T18:10:33", "published_display": "06 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BNP Paribas raises the target price for Genmab to 2,500 Danish kroner (2,400), reiterates outperform - BN", "summary": "BNP Paribas has increased its target price for Genmab to 2,500 Danish kroner, up from 2,400, while maintaining an \"outperform\" rating. This adjustment reflects a positive outlook on the biotechnology company's future performance. The article also provides recent news on Genmab's ", "url": "https://www.marketscreener.com/news/bnp-paribas-raises-the-target-price-for-genmab-to-2-500-danish-kroner-2-400-reiterates-outperform-ce7f5edbd888f421", "source_name": "www.marketscreener.com", "published_at": "2026-07-06T13:10:47", "published_display": "06 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Europe approves Genmab's TEPKINLY combo for relapsed follicular lymphoma", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNQnU3NnNXVm9lM3FhOFF2MUNidnZKaEZQeFBLWUZIQXRvWFp2YnJUNDNMaDgzSDJPb1ljWWw3UDd1a0xjQko4TnRITkNfZTI3dHZ6N2gybGs2SUJIdzFZZ1N4UkN1SlI2Z2JVQVBmd3N4dklJcFdoVEdxWVd6Tms0LUtlRURFY0ZyVTJnM2JuNTRqYklOQS1mYURLUnViV042S202SlBHQkZJRzJnWTd0TEpn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GMAB - Genmab ADR Earnings", "summary": "This Finviz article provides a detailed financial overview of Genmab ADR (GMAB), including its last closing price, key financial metrics like market cap, income, sales, P/E ratio, and EPS. It also lists performance indicators, insider ownership, institutional ownership, and analy", "url": "https://finviz.com/stock?t=GMAB&p=d&b=2&r=m3&ty=ea", "source_name": "Finviz", "published_at": "2026-07-04T10:39:10", "published_display": "04 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Genmab stock price target on trial success", "summary": "H.C. Wainwright has increased its price target for Genmab A/S shares to $40 from $38, maintaining a Buy rating, following successful trial results for the drug EPKINLY. The trial demonstrated a statistically significant improvement in progression-free survival for diffuse large B", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-genmab-stock-price-target-on-trial-success-93CH-4772913", "source_name": "Investing.com", "published_at": "2026-07-02T14:10:24", "published_display": "02 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab shares rise following positive epcoritamab phase 3 data", "summary": "Genmab shares rose after the company and AbbVie announced positive phase 3 results for their drug epcoritamab. The drug, in combination with lenalidomide, significantly improved progression-free survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL", "url": "https://european-biotechnology.com/latest-news/genmab-positive-phase-3-data-epcoritamab-combination/", "source_name": "European Biotechnology Magazine", "published_at": "2026-07-01T06:41:12", "published_display": "01 Jul 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab and AbbVie\u2019s Epkinly combo improves PFS in second-line DLBCL trial", "summary": "Genmab and AbbVie have announced positive topline results from their Phase III EPCORE DLBCL-4 trial, showing that Epkinly in combination with Revlimid significantly improved progression-free survival in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Thi", "url": "https://www.clinicaltrialsarena.com/news/dlbcl-epkinly-second-line-data/", "source_name": "Clinical Trials Arena", "published_at": "2026-07-01T01:40:18", "published_display": "01 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie, Genmab Blood-Cancer Drug Has Competitive Profile -- Market Talk", "summary": "AbbVie and Genmab's investigational blood cancer drug, epcoritamab, has shown a competitive profile in a Phase 1/2 study, according to analysts at Jefferies. The drug, a bispecific antibody, demonstrated a 60% complete response rate in patients with large B-cell lymphoma, reinfor", "url": "https://www.moomoo.com/news/post/72269984/abbvie-genmab-blood-cancer-drug-has-competitive-profile-market-talk", "source_name": "Moomoo", "published_at": "2026-07-01T01:09:27", "published_display": "01 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After monotherapy failure, AbbVie and Genmab tout Epkinly combo win in DLBCL", "summary": "AbbVie and Genmab's Epkinly, despite a recent monotherapy failure, showed a significant win in a Phase 3 combination trial for diffuse large B-cell lymphoma (DLBCL). The drug, combined with lenalidomide, reduced the risk of progression or death by 60% compared to the R-GemOx regi", "url": "https://www.fiercepharma.com/pharma/after-monotherapy-failure-abbvie-and-genmab-tout-epkinly-combo-win-dlbcl", "source_name": "Fierce Pharma", "published_at": "2026-06-30T13:39:58", "published_display": "30 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival", "summary": "Genmab announced positive topline results from its Phase 3 EPCORE DLBCL-4 trial, showing that epcoritamab combined with lenalidomide significantly improved progression-free survival in patients with relapsed/refractory diffuse large B-cell lymphoma. The combination reduced the ri", "url": "https://www.businesswire.com/news/home/20260629433290/en/Genmab-Announces-Positive-Phase-3-Results-for-Epcoritamab-Plus-Lenalidomide-in-Patients-with-RelapsedRefractory-Diffuse-Large-B-Cell-Lymphoma-Demonstrating-Statistically-Significant-Improvement-in-Progression-Free-Survival", "source_name": "Business Wire", "published_at": "2026-06-30T12:41:12", "published_display": "30 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial", "summary": "Genmab's shares increased in European morning trading after its drug combination with partner AbbVie met the primary goal in a late-stage clinical trial for lymphoma. The stock rose 6%, recovering some year-to-date losses, though it remains down 10% since the start of 2026. AbbVi", "url": "https://www.wsj.com/health/pharma/genmab-shares-climb-after-lymphoma-therapy-hits-goal-in-trial-64ebf887", "source_name": "WSJ", "published_at": "2026-06-30T09:39:31", "published_display": "30 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab stock rallies after Epkinly shows strong results in 2L lymphoma trial", "summary": "Genmab shares surged after its drug Epkinly, combined with lenalidomide, delivered strong interim data in a late-stage trial for second-line diffuse large B-cell lymphoma. The results showed a progression-free survival hazard ratio of 0.40, easing previous investor concerns after", "url": "https://www.investing.com/news/stock-market-news/genmab-stock-rallies-after-epkinly-shows-strong-results-in-2l-lymphoma-trial-4767021", "source_name": "Investing.com", "published_at": "2026-06-30T08:39:32", "published_display": "30 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab\u2019s Epcoritamab Plus Lenalidomide Meets Phase 3 Goal in Relapsed DLBCL", "summary": "Genmab's Phase 3 EPCORE DLBCL-4 trial for epcoritamab plus lenalidomide in relapsed or refractory DLBCL patients met its primary endpoint, showing a 60% reduction in disease progression or death risk compared to R-GemOx. This significant result, with a hazard ratio of 0.40 (U.S.)", "url": "https://www.clinicaltrialvanguard.com/news/genmabs-epcoritamab-plus-lenalidomide-meets-phase-3-goal-in-relapsed-dlbcl/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-06-30T06:39:32", "published_display": "30 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab reports positive phase 3 trial results for lymphoma drug", "summary": "Genmab A/S announced positive Phase 3 trial results for its lymphoma drug epcoritamab, showing statistically significant improvement in progression-free survival for patients with relapsed or refractory diffuse large B-cell lymphoma. The company reported strong financial momentum", "url": "https://www.investing.com/news/company-news/genmab-reports-positive-phase-3-trial-results-for-lymphoma-drug-93CH-4766234", "source_name": "Investing.com", "published_at": "2026-06-30T00:12:41", "published_display": "30 Jun 2026 00:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab lymphoma trial cuts progression risk 60% in phase 3 study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNckZUcExPdF92eDZNTC1FamFmaUhwUUFiYTE0OGVxN1FoVFFUMHo4ZEJGS05ZNzFDaTB5RkxnT05lZVplV3BjVWtKVDdHZ3kyMEVNdjJVWWVSSVFhellVR19xRy1TZkd4Q0Q2aktLMThLRGpEYUtjdjdkYkhhUTR4WTRqSTBSempudWxiaWVpbGgzY3BUb3hCYXJ3VE92Ym9ZcDRqWmdQZll1SUhralprczkzeGwwVi1w?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (NASDAQ: GMAB) issues 185 new shares from employee warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQcFd2MVlaM2k1S0NWcFhRSTBLb2ZLZTdZSVB4bjRIUjVvT3VJUUc0MHpyZGZfRGgyYzRjZmFQMEl4ZTlET3pYM3ZBcXRHT0R1cTJYeDBWX3VkTUZ4Y21IblBFZE5kMlc4NWxsOFRrQ25DVXQ4U282TmF4YldiLUVUVzRQTWRnN3pORldpeXhCTFZ0VXBlWXJnWG1PRFcwOTY1YTNXTEh6SVRiQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab\u2019s epcoritamab phase 3 lymphoma results set for ASCO and EHA 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSEdhWGhwYXZIaDRubmctcF9WdTNQX3FfMjlULWJySy1ZLW9VWVNYX0JsWkRLdm5LUHlROGZ5U3llRktocVhPZ2tKbHpLal9rNFBaZFhHTEh2c29qVXNXX2RsaUIzNkw2R0pydkFGcWxZS1NMZndYOFVuQ2dNX085Y1VKbi1reG9ySEVISGJzMXo2TVVNQTZmMVh0UFZrcXVMQUdNNERVYnF1NE1uUUJCSHhCUUE3WVdBVUFGTw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNLWV6MExvM1NSUEJ5eE5CaU1tZERrby1IaFFnN2IxR2xpWFo0NjVZczY1VUkyT3g4NWI5TU8tMm5iaGVQdU90eEVmMXhoRzhzQnBBd3hSTUdHaTJRSFo3REJHLUpLWjRPSVRPYVNlOFl5SGc5d0VCM1Q2b3JmZ29DOGFla0RManlPdFR4bEVLRnAxbEljNThRdU90aDczdw?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capital Increase in Genmab as a Result of Employee Warrant Exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPQlJRQzVVdU1IM1ZLT1ZYZXlMWkMzR2ZrUFREUU0zaDRINVVxc1g1RU1zUVQ2MzRmVlZzcTR4dzF1ZG5kVWFEXzhVWktCWHktUDRnbmZiSEl1UmVVbUMyTzZHZlFDd0F3T3J0REZtUEYyWHpPaXo5NTBROVVRNHlpcW9vcTJQcHNhX1NTTjh1OHVXWUcwWkljLXBUdkxNNDc2bENESFhfbw?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab plunges after financial report: Analyst cites uncertainty surrounding clinical trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9lbXZVemZVQUV1VkdYb2pQWTBERzFHdHZzcHIxTVVyX0VwRFIyWWZOS2N0TVdkUVIwRmY1dHdRRzRPY2o5OGx5dDZiQjJPUGJaQmI0MUhrT1V5LWR3bjcwOEQ1TEM5ZGNhWW9lWVo2MA?oc=5", "source_name": "medwatch.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi\u2011Year Share Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOUjhiOXlYYkF3RHFBUXVPY2tTbzQ4VlJCandIeDhHMmJrZzl5YWIyVDA2UmRXTTFSLWFlMnNrRnFlcHROUVdZUnVsVHBaSTljOEphVFM2bkhtZWJTbk1fekc2OWVYZnRZLU9VZ3FFT1ZrOVhsNlZxdzFrei1HTWxtdk1lazVfN0xzY0x1Z2ZidWFaNkk4UUdUYUlhNA?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (GMAB) stock falls on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNaUh6a2RmMnNjNFB2VnI3MTNTTGlfWTl6WExfRFhzRHRJOHJhdzhYbkNld0NaLUFpekFfemdPbmdSM1pCaG5hcEZTaGQ2WEhZWGJqSXZReWh0djNMZDlrUjZQSWZVbHJaRERwQ0dpRkFBclBZZ29HT1Fvc2VueFFvMG8wR2hMUEZKeDIzZlVaWEhpQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Rated Outperform on Oncology Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZmpxd1NpbTVHX3pZc2VyVjVpWVliSUNWYmFLbmZObkk2ejdmc0k1ME9ZdEwwZjFhVkNIblYyMTJBdWF5NlZfeVVueldkbU9Ydi1EUERPYnVsVUp0cm0wRmZqcXdwOXpZV2tyVXFndWppZHg4a21GN0JQQW9RNzVlUnJpMndkZHJreXNOUEFxZ2VCaHE1ZkhMTDJFT083X1FDMjdneDVvRnBRZw?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Genmab\u2019s (CPSE:GMAB) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQOXhrV3ZBMURTTVVITTdQZ1Z3YzYxUE40alV4bEJ1VjN4N19rbTdmdkN1NWVWdThHeXFiOE5WNnotWEFVcE1GVTBIS1dOdzZPNVFWdUxmLUdqM3VCbHdWa09hWGJ5R0JUek9OQnRDZFBISnNfU3NrblpYTGtuTGZKcFFtcXpKaldOT1VMbE9aNHR0WnI3WmVxYjhWd1g?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab Readouts", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNQk9kRTlPdmQtaF9uUVhlTXhHSjIxd1JJZ2toUEJTUXQ0c3k4N3dqNlNva0VvREJYYWVwaHVNQTBHUm5zbVd6MGZ6OHQya1JPRk5QZ0JvUnhGU21OR1hZNmxQR0FOTDRPTElWUnZ3aThqYXhBdU1aa1ZodVgxWGhMTDRoemtoeFd6TFdnd2hLUi1nN2FFUlpBSkg1ZFVzNVJl?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Constitution of the Board of Directors in Genmab A/S and", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogJBVV95cUxQbUlOd0tVamZ5SkFqV2NYcWVlTU5CenRhVjNKYU50Y1pGZ1VKcnFMbkVaZW10VGZ1OW9Rb2NPc2YwSnJpRXYtNWFyNmdkTjB3OVdCUmw0ZDRSbF91OGxWRWVVaFBoSWU1cEVybl9DNVNFZEVZbXJRYWtSSlV0bkpMRThiYWE2SGNaS1U2YUJzZEJBaFExMFdLR0FPenNXakhWZ0Z6VkkzZG1GTm9CM0RoQ2szN3gyVkp3MkFYWUdSQmdIWTJjSDloUzFtZnVFWDlUS01yQmlIT3lpaDlqeW5KTnhWZmljNHk2R05TbGptRXg4c3BHNXFJdHZRNlRJdnRfaFZJU1I2ZDBvdGJPSmxLeHZBV1o1LVhUUXNkd1RUdW95Zw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNdnJwT19rRjVEN3JfUnBWTlJ1bUZZUG1tRWJBX21KYWtDcmJWWkw5MnVOaWgwR0JKeXQwUkU4cU9yOG54R0NiMnoxc1czbjV6eXZyOVV5eHMxb1dtbjExbmUtNXp1UHFocVUwZjFrRHhHYlVDb2xfd3ZNYnVIbGlVczM5aFh6bF82WmJ5eWlpVHdqWHJfa3Z1Vnp2ZDRmRHBaM2RQZ1NNOWRRUzE5QWh3SW8zcFExUDZvRkVKZVRSdVBsZw?oc=5", "source_name": "ChartMill", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Genmab (CPSE:GMAB) Narrative Is Shifting As 2026 Catalyst Risks Build", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNOTZnQTlGYnljWm1NT25BN2tRQVl4dzNqZWIyZU5mOG04MHE1WWJCZTVad2RIaFdXS3l6QUJuTTg0ZjBNWjh0SUNfeU1ZTUtubWtyYWZFZnozWWZjZWxDaWtmQXNYYXdoVWt3UjhIbURYM19CS21FUkZLUl95Tmt1TlljR0dpLW5S?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNcm5lb2IwQUhyVEFlYmFRaG40U0lzUzdOVU5HVzd3ZDFiQk96RHdLWUxVTXcwUGt0MUhCZkloUjQ4akwwUG5WMzZZSGN2N252ajZyMmgyTGp0OExvYlZJby1UQUtFSlhYRUVkQ210YmZkNE8yVXBnQ0RVYnRFMXhMT09R?oc=5", "source_name": "Market source", "published_at": "2026-02-20T08:00:00+00:00", "published_display": "20 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Where is Genmab A/S (GMAB) Headed According to Wall Street?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPOGV2M016ZC13NEpIa05vR1ZUNHpiR3Q0amVPajRJRHdqczBYWGhjYVdydFhmRWhYWlZnaGVSYUhnX2tKNVo5cDU5bEdfaDJYTWV0WFdJMWVmY21ZbUVRSjJ1cGRNMTJMV0tpUmFRNVU2SDNmX0hKZmJoR2JMMlZUQ1Z0dS1lbTA?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB)\u2019s Future Potential Underappreciated by Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOWWlrWWpHU1pOaVU2TlAzaUhtQ19uc3kzU0htYzJyYUJGeTJCRlI3RHRqT21VYzUzYVYxVGhvQVFaWDhtVmtzQktDVUNCS3pjUGxYeFBfbkU4eG1zRnd2X1RKRVhmbTREeFI5NTZ2azFvdW92LTE2dmt1WUpOV3NDRWlNc2M1bWhFYUpwcndmWVhGeWxWOFE?oc=5", "source_name": "Market source", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxOTmUtQjcyV1RXS0ZpVW9fN3BRcHpSd0NwQkxyN1ZLT2tpa2JGX1FSYWhmTm91OEtESktublRWdkFxRkhBYkxiT0NMOVY2UzVGcGlHazJQWC1Nd200a1VpMFBoeWlyaWdvMDUtbm5MRTRuczZBM0tmVk9pcklCcy1YTGNzSzNQT00yYmkzMWhudHd0LUFUSWgxMmJyT3VhTGZ1T05ObWxOZ2FWVXc5LWRZLTZyaTl6Y2NkLS15d2laZUI4V0N0ZUhkTlJMVVNtUmxUWGQ3dVFSUFNrS0VfVlllUHQyd0RNRGMtUWJIaWdRUDFkM1h1MzdLblEzWQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9nUGpGYzh6QmdvN1BZWHdXekdheFpxVkYyYlVPQnBVWmFTQVlMOHJNSGhPbFJsMnlLS2MwTkJtX29uLW5RdklPQUFiazBYQkFtM1Vr?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T22:48:32+00:00", "published_display": "24 Apr 2025 22:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 56, "sentiment_summary": {"positive": 20, "negative": 5, "neutral": 31, "score": 59, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 13.0, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 10.31, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 29.0, "latest_week": "2026-07-10", "one_week_move": 1.7, "four_week_move": 15.6, "twelve_week_move": 1.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.500644, "market_dynamics_buy_signal": false, "relative_strength": -12.419209, "fair_value_gap": 6.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 53.8234, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.7% over one week, +15.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 17}, {"label": "Stock Titan", "count": 6}, {"label": "GlobeNewswire", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "MT Newswires", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "TradingView", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 21}, {"label": "Analyst action", "count": 6}, {"label": "Regulatory and legal", "count": 5}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.7% over one week, +15.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Genmab (GMAB)"}], "updated_at": "2026-07-17T15:24:47.254791+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}